NGM Biopharmaceuticals, Inc.

NasdaqGS:NGM Rapport sur les actions

Capitalisation boursière : US$128.5m

NGM Biopharmaceuticals Croissance future

Future contrôle des critères 2/6

NGM Biopharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 14.7% et de 57.6% par an respectivement. Le BPA devrait croître de de 20.3% par an. Le rendement des capitaux propres devrait être -230.7% dans 3 ans.

Informations clés

14.7%

Taux de croissance des bénéfices

20.3%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices23.8%
Taux de croissance des recettes57.6%
Rendement futur des capitaux propres-230.7%
Couverture par les analystes

Low

Dernière mise à jour12 Mar 2024

Mises à jour récentes de la croissance future

Recent updates

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

Dec 19
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Oct 05
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Aug 09
Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Jun 27
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Apr 17
NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

Dec 20
We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Oct 17

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

Jun 30

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Jun 21

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jun 15
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

May 09
Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

Apr 26

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Feb 21
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Nov 08
We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jul 09
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 06
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:NGM - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20269-90-88-464
12/31/20250-94-89-785
12/31/20240-98-77-693
12/31/20234-142-133-132N/A
9/30/202322-151-141-140N/A
6/30/202330-170-142-141N/A
3/31/202337-178-153-151N/A
12/31/202255-163-146-144N/A
9/30/202258-153-134-132N/A
6/30/202269-135-115-114N/A
3/31/202277-125-89-87N/A
12/31/202178-120-75-73N/A
9/30/202177-121-77-75N/A
6/30/202182-122-93-91N/A
3/31/202185-111-88-87N/A
12/31/202087-102-85-83N/A
9/30/202099-90-81-78N/A
6/30/202097-72-62-60N/A
3/31/2020102-54-50-48N/A
12/31/2019104-43-45-41N/A
9/30/2019120-13-22-20N/A
6/30/2019119-9-22-19N/A
3/31/2019116-5-22-15N/A
12/31/20181090-13-8N/A
9/30/201881-17-24-18N/A
6/30/201880-12-22-15N/A
3/31/201877-13-21-16N/A
12/31/201777-14-24-17N/A
12/31/201686-7N/A1N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: NGM devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: NGM devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: NGM devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de NGM ( 57.6% par an) devrait croître plus rapidement que le marché US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de NGM ( 57.6% par an) devrait croître plus rapidement que 20% par an.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: NGM devrait être non rentable dans 3 ans.


Découvrir les entreprises en croissance